当前位置: X-MOL 学术J. Adolesc. Young Adult Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Outcomes of Osteosarcoma in Children Without High-Dose Methotrexate: Could It Be Less Toxic Without Effecting Survival Rates?
Journal of Adolescent and Young Adult Oncology ( IF 2 ) Pub Date : 2022-06-07 , DOI: 10.1089/jayao.2021.0075
Nurşah Eker 1 , Ayşe G Tokuc 1 , Barış Yılmaz 2 , Zeynep Aktaş 3 , Onur Buğdaycı 4 , Bülent Erol 5 , Emel Senay 2 , Seda Aras 1
Affiliation  

Background: Osteosarcoma (OS) is the most common primary bone sarcoma in childhood. High-dose methotrexate, doxorubicine, cisplatin, and/or ifosfamide combinations are used as standard treatment in chemotherapy and could cause serious toxicity. Another alternative chemotherapy protocol is consisting of epirubicin, ifosfamide, and cisplatin (ECI), which we use in our center. The aim of this study was to evaluate the patients with OS who were treated with ECI protocol, retrospectively.

中文翻译:

没有大剂量甲氨蝶呤的儿童骨肉瘤的结果:在不影响存活率的情况下,它的毒性会降低吗?

背景:骨肉瘤(OS)是儿童期最常见的原发性骨肉瘤。大剂量甲氨蝶呤、多柔比星、顺铂和/或异环磷酰胺组合用作化疗的标准治疗,可能会导致严重的毒性。另一种替代化疗方案由我们中心使用的表柔比星、异环磷酰胺和顺铂 (ECI) 组成。本研究的目的是回顾性评估接受 ECI 方案治疗的 OS 患者。
更新日期:2022-06-09
down
wechat
bug